恩凯赛药-NK CellTech

NK CellTech is committed to the innovation of NK cell therapies through technologies of synthetic immunology, including logic circuits, feedback switches and intelligent control system. NK cells are quantified, controlled and being intelligent through gene manipulation and these modified NK cells could resolve the unmet clinical needs of cancer patients and those with other diseases.

Science&
Technology

The R&D team has over 30 years of experiences in the research and application of NK cells.

Pipeline

A robust pipeline with novel NK cell products.

Product

Description

Indication

Discovery

Preclinical

IND filing

NK-010

PBMC-NK

1. Ovarian

2. Solid

3. AML

NK-011

PBMC-Memory NK

Tumor

NK-042

NKR-NK

Tumor

NK-043

NKR-NK

Tumor

NK-062

NKR-NK+

Tumor

NK-063

NKR-NK+

Tumor

NK-081

Bi-NKR/CAR+

Tumor

NK-082

Bi-NKR/CAR+

Tumor

NK-091

Syn-NK+

Tumor

NK-092

Syn-NK+

Tumor

Investors

NK CellTech announced its completion of series A financing round valued at more than 100 million CNY.

About Huagai Capital

Huagai Capital is a private equity firm co-founded by a group of professionals from leading domestic and international investment institutions founded in 2012. Currently, the company manages approximately 20 billion CNY in assets. With the vision of "becoming the most trusted capital partner for entrepreneurs and investors", the firm focuses on private equity investments in two major fields: healthcare and technology, and is committed to promoting the growth of SMEs into industry leaders.

About CAS FOF

The CAS Fund of Funds (“CAS FOF”) is a major strategic arrangement decided by the Chinese Academy of Sciences (CAS) to implement the guiding principle of president Xi Jinping's speech during his inspection to the CAS. Aiming to support and promote the technology transfer within the CAS system, the CAS FOF is an exploration and practice of the new national mechanism in the field of scientific and technological innovation. The CAS FOF makes it its mission to solve the stranglehold problems in the core technological fields of China, and implements the innovation-driven development strategy. Relying on the profound scientific and technological resources of the CAS, the CAS FOF applies the investment mode of “FOF (fund of funds) + direct investment” to mainly invest in strategic emerging industries and such key stranglehold technologies as “key technology” and “green technology”, and takes “technology + finance” as the link to build a nationwide platform and investment system for the technology transfer, thus realizing the common improvement of the national strategy of innovation-driven development, social responsibilities and economic value.

About Unifortune Group

Unifortune Group, founded in 2011, is committed to become an integrated holding group by leading innovation with technology and serving the real economy. Adhering to the concept of "technology empowers finance, finance serves industry, industry services to the society", Unifortune has been deeply involved in China's economic development and industrial upgrading. Unifortune focuses on private equity investment, industrial investment, special opportunity investment and many other asset management businesses. Unifortune has a number of member companies like Unifortune Investment Fund Management Ltd, which focuses on medical & health, advanced manufacturing and new energy fields, and China Xinxing Asset Management Ltd.

About Nanjing Chase Capital

Founded in 2015, Chase Capital focuses on early and growing stage biopharmaceutical, technological and innovative investments in Nanjing and the Yangtze River region. The fund size is about 2 billion CNY. In biopharmaceutical field, Chase Capital has invested in a number of outstanding companies representing the future, including Ab&B Biotech, Biosion Inc, Nanjing Kati, Innovo Therapeutics, etc. In addition to capital assistance, Chase Capital is committed to helping and promoting growth and innovatioin of its portfolio companies on all fronts and at multiple levels, driving revolution on industry and society.

About Sirius Capital

Founded in 2015 by a group of professional investors with rich investment experience and excellent industry resources, Sirius Capital is a private venture capital firm focusing on the investment of technology innovative companies and is committed to identify the best entrepreneurs in China which type is "scientist + entrepreneur". Hard technology and life science are the key areas that Sirius Capital continues to focus on. Sirius Capital believes that NK CellTech will make outstanding contributions to the protection of human health in the frontier medical field of immune cell therapy by relying on its top international R&D strength.

About Qiaojing Capital

Founded in 2013, Qiaojing Capital is an angel incubation fund focused on healthcare investments, with particular interest on medical devices, biopharmaceuticals and innovative biotechnology. Qiaojing Capital always insists on value investment based on clinical needs in the medical field, and is committed to cultivating new medical technologies, providing better solutions for domestic clinics, and helping the development of human medical business.

NEWS

2024-01-22

NK CellTech Announces FDA Clearance for Clinical Trial of NK010

2022-06-02

NK CellTech Chairman Zhigang Tian elected member of Academia Europaea

The turn of spring and summer has brought us a string of good tidings and great joy. Mr. Zhigang Tian, a member of the Chinese Academy of Engineering, professor of the University of Science and Technology of China and chairman of NK CellTech......